プロカルバジン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

  H315：皮膚刺激

  H319：強い眼刺激

  H335：呼吸器への刺激のおそれ

  H351：発がんのおそれの疑い

  H361：生殖能または胎児への悪影響のおそれの疑い

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

MSDS Information

• N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide

プロカルバジン 化学特性,用途語,生産方法

• 効能

  抗悪性腫瘍薬

• 化学的特性

  Procarbazine is a white to pale yellow crystal- line powder with a slight odor.

• 使用

  antibacterial

• 定義

  ChEBI: A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procar azine and hydrogen peroxide, which results in the breaking of DNA strands.

• 適応症

  Procarbazine (Matulane) may autooxidize spontaneously, and during this reaction hydrogen peroxide and hydroxyl free radicals are generated. These highly reactive products may degrade DNA and serve as one mechanism of procarbazine-induced cytotoxicity. Cell toxicity also may be the result of a transmethylation reaction that can occur between the N-methyl group of procarbazine and the N7 position of guanine.

• 作用機序

  Procarbazine is rapidly absorbed after oral administration and has a plasma half-life of only 10 minutes. The drug crosses the blood-brain barrier, reaching levels in CSF equal to those obtained in plasma. Metabolism is extensive and complex. Urinary excretion accounts for 70% of the procarbazine and its metabolites lost during the first 24 hours after drug administration.

• 臨床応用

  When originally tested as a single agent in advanced Hodgkin’s disease, procarbazine produced tumor regression responses that were brief, usually lasting only 1 to 3 months. The combination of procarbazine with mechlorethamine, vincristine, and prednisone in the MOPP regimen, however, resulted in an 81% complete remission rate in Hodgkin’s disease. Most of these patients are considered cured. Procarbazine is also used in various combination chemotherapy protocols for non- Hodgkin’s lymphomas and small cell anaplastic (oat cell) carcinoma of the lung. Limited antitumor effects have been observed against multiple myeloma, melanoma, and non–oat cell lung cancers.

• 副作用

  The major side effects associated with procarbazine therapy are nausea and vomiting, leukopenia, and thrombocytopenia. Skin rashes have been reported, as have rare cases of allergic interstitial pneumonia. Procarbazine administration produces a high degree of chromosomal breakage, and the compound is mutagenic, teratogenic, and carcinogenic in experimental systems.
  Procarbazine may potentiate the effects of tranquilizers and hypnotics. Hypertensive episodes can result if procarbazine is administered simultaneously with adrenomimetic drugs or with tyramine-containing foods. Rarely, a reaction to alcohol similar to that provoked by disulfiram may occur.

• 職業ばく露

  Procarbazine is available in capsule form. The primary use of this drug is as an antineoplastic agent in the treatment of advanced Hodgkin’s disease, and oat-cell carcinoma of the lung. The hydrochloride com- pound is used in treatment. The FDA approved use of pro- carbazine hydrochloride in 1969 and indicated that the drug should be used as an adjunct to standard therapy. Possible exposure occurs during manufacture of the drug and direct exposure during its subsequent administration to patients. Some of the metabolites of procarbazine hydrochloride are both carcinostatic and carcinogenic.

• 発がん性

  Procarbazine and procarbazine hydrochloride are reasonably anticipated to be human carcinogens based on sufficient evidence of carcinogenicity from studies in experimental animals. The names “procarbazine” and “procarbazine hydrochloride” are used interchangeably in published studies; because only procarbazine hydrochloride is produced, it has been assumed that procarbazine hydrochloride was the substance under study.

• 輸送方法

  UN2811 Toxic solids, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, Technical Name Required.

• 不和合性

  Incompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, epoxides.

• 廃棄物の処理

  It is inappropriate and possibly dangerous to the environment to dispose of expired or waste drugs and pharmaceuticals by flushing them down the toilet or discarding them to the trash. Household quantities of expired or waste pharmaceuticals may be mixed with wet cat litter or coffee grounds, double-bagged in plastic, discard in trash. Larger quanti- ties shall carefully take into consideration applicable DEA, EPA, and FDA regulations. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

プロカルバジン 生産企業

Global(75)Suppliers

671-16-9, プロカルバジン キーワード